Ausdal Financial Partners, Inc. Acelrx Pharmaceuticals Inc Transaction History

Ausdal Financial Partners, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	BUY	$0.2 - $0.35 $2,000 - $3,500	10,000 Added 62.5%	26,000 $5,000
Q3 2020 Nov 04, 2020	BUY	$1.01 - $1.81 $5,050 - $9,050	5,000 Added 45.45%	16,000 $23,000
Q2 2020 Aug 06, 2020	SELL	$1.03 - $1.69 $4,120 - $6,760	-4,000 Reduced 26.67%	11,000 $13,000
Q1 2020 May 04, 2020	SELL	$0.76 - $2.07 $456 - $1,242	-600 Reduced 3.85%	15,000 $21,000
Q4 2019 Feb 14, 2020	SELL	$1.66 - $2.4 $6,689 - $9,672	-4,030 Reduced 20.53%	15,600 $27,000
Q4 2018 Feb 11, 2019	SELL	$2.13 - $4.8 $575 - $1,296	-270 Reduced 1.36%	19,630 $45,000
Q3 2018 Nov 09, 2018	BUY	$2.6 - $4.6 $806 - $1,426	310 Added 1.58%	19,900 $77,000
Q2 2018 Aug 08, 2018	BUY	$2.13 - $4.2 $41,726 - $82,278	19,590 New	19,590 $66,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Ausdal Financial Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Ausdal Financial Partners, Inc. with notifications on news.